Key result
Left ventricular assist device support in end-stage heart failure significantly decreased soluble ST2 levels from 74.2 ng/mL pre-implantation to 29.5 ng/mL during support (P < .001).
Why the study?
Does left ventricular assist device (LVAD) support reduce soluble ST2 levels in patients with end-stage heart failure?
Population
38 patients with end-stage heart failure undergoing left ventricular assist device (LVAD) implantation.
Comparison
Left ventricular assist device (LVAD) support vs Pre-implantation baseline
Design
Cohort
Follow-up
6 months
Authors
Loading...
LVAD unloading may lower sST2 in advanced HF; leaves open whether this improves outcomes or guides therapy.
Cohort (n=38)
Does left ventricular assist device (LVAD) support reduce soluble ST2 levels in patients with end-stage heart failure?
Absolute Event Rate: 29.5% vs 74.2%
p-value: p=<.001
LVAD support in end-stage heart failure significantly reduces elevated sST2 levels, suggesting a lessening of fibrosis and inflammation.
Tseng et al. (2018) conducted a cohort in end-stage heart failure (n=38). Left ventricular assist device (LVAD) support vs. Pre-implantation baseline was evaluated on soluble ST2 (sST2) levels (p=<.001). Left ventricular assist device support in end-stage heart failure significantly decreased soluble ST2 levels from 74.2 ng/mL pre-implantation to 29.5 ng/mL during support (P < .001).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: